Mosby's 2014 Nursing Drug Reference (25 page)

BOOK: Mosby's 2014 Nursing Drug Reference
4.65Mb size Format: txt, pdf, ePub
aliskiren (Rx)

(a-lis′kir-en)

Tekturna

Func. class.:
Antihypertensive

Chem. class.:
Direct renin inhibitor

ACTION:

Renin inhibitor that acts on the renin-angiotensin system (RAS)

USES:

Hypertension, alone or in combination with other antihypertensives

CONTRAINDICATIONS:

Hypersensitivity

 

Black Box Warning:

Pregnancy (D) 2nd, 3rd trimester

Precautions:
Pregnancy (C) 1st trimester, breastfeeding, children, geriatric patients, angioedema, aortic/renal artery stenosis, cirrhosis, CAD, dialysis, hyper/hypokalemia, hyponatremia, hypotension, hypovolemia, renal/hepatic disease, surgery, diabetes, seizures

DOSAGE AND ROUTES
Calculator

• Adult: PO
150 mg/day, may increase to 300 mg/day if needed, max 300 mg/day

Available forms:
Tabs 150, 300 mg

Administer:

• 
Do not use with a high-fat meal

• 
Daily with a full glass of water, titrate up to achieve correct dose

• 
Do not discontinue abruptly, correct electrolyte/volume depletion before treatment

SIDE EFFECTS

CV:
Orthostatic hypotension, hypotension

CNS:
Headache, dizziness

GI:
Diarrhea

GU:
Renal stones, increased uric acid

INTEG:
Rash

META:
Hyperkalemia

MISC:
Angioedema,
cough

PHARMACOKINETICS

Poorly absorbed, bioavailability 2.3%, peak 1-3 hr, steady state 7-8 days, 91% excreted unchanged in the feces, half-life 24 hr

INTERACTIONS

• 
Do not use ACE inhibitors, angiotensin II receptor antagonists in diabetes mellitus

Increase:
potassium levels—ACE inhibitors, angiotensin II receptor antagonists, potassium supplements, potassium-sparing diuretics

Increase:
hypotension—other antihypertensives, diuretics

Increase:
aliskiren levels—atorvastatin, itraconazole, ketoconazole, cyclosporine; concurrent use is not recommended

Decrease:
levels of warfarin

Drug/Food

Decrease:
absorption—high-fat meal

Drug/Lab Test

Increase:
uric acid, CPK, BUN, serum creatinine, potassium

Decrease:
Hct, Hgb

NURSING CONSIDERATIONS
Assess:

• 
Renal studies: uric acid, serum creatinine, BUN may be increased; potassium, hyperkalemia may occur

 
Allergic reactions: angioedema
may occur (swelling of face; trouble breathing, swallowing)

• 
Daily dependent edema in feet, legs; weight, B/P, orthostatic hypotension

• 
Diabetes:
identify the use of ACE inhibitors, angiotensin II receptor antagonists, do not use aliskiren

Perform/provide:

• 
Storage in tight container at room temp

Evaluate:

• 
Therapeutic response: decrease in B/P

Teach patient/family:

• 
About the importance of complying with dosage schedule even if feeling better; that if dose is missed, take as soon as possible; that if it is almost time for the next dose, take only that dose; do not double dose

 

Black Box Warning:

To notify if pregnancy is planned or suspected; if pregnant, product will need to be discontinued, pregnancy (D) 2nd/3rd trimester, (C) 1st trimester

• 
How to take B/P and normal reading for age group

• 
Not to use OTC products including herbs, supplements unless approved by prescriber

• 
To report to prescriber immediately: dizziness, faintness, chest pain, palpitations, uneven or rapid heart beat, headache, severe diarrhea, swelling of tongue or lips, trouble breathing, difficulty swallowing, tightening of the throat

• 
Not to operate machinery or perform hazardous tasks if dizziness occurs

• 
To avoid faintness; to rise slowly

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

allopurinol (Rx)

(al-oh-pure′i-nole)

Aloprim, Zyloprim

Func. class.:
Antigout drug, antihyperuricemic

Chem. class.:
Xanthene oxidase inhibitor

Do not confuse:
Zyloprim
/Zovirax

ACTION:

Inhibits the enzyme xanthine oxidase, reducing uric acid synthesis

USES:

Chronic gout, hyperuricemia associated with malignancies, recurrent calcium oxalate calculi, uric acid calculi

CONTRAINDICATIONS:

Hypersensitivity

Precautions:
Pregnancy (C), breastfeeding, children, renal/hepatic disease

DOSAGE AND ROUTES
Calculator
Increased uric acid levels in malignancies

• Adult: PO
600-800 mg/day in divided doses for 2-3 days; start up to 1-2 days before chemotherapy;
IV INF
200-400 mg/m
2
/day, max 600 mg/day 24-48 hr before chemotherapy, may be divided at 6-, 8-, 12-hr intervals

• Child 6-10 yr: PO
300 mg/day, adjust dose after 48 hr

• Child
<
6 yr: PO
150 mg/day, adjust dose after 48 hr

• Child:
IV INF
200 mg/m
2
/day, initially as a single dose or divided q6-12hr

Recurrent calculi

• Adult: PO
200-300 mg/day in a single dose or divided bid-tid, max 300 mg/dose, 800 mg/day

Uric acid nephropathy prevention

• Adult and child
>
10 yr: PO
600-800 mg/day × 2-3 days

Gout (mild)

• Adult: PO
100 mg/day, increase weekly based on uric acid levels, max 800 mg/
day; maintenance dose 100-200 mg bid-tid

Gout (moderate-severe)

• Adult: PO
400-600 mg/day in a single dose or divided bid-tid, max 800 mg/day, doses >300 mg should be given in divided doses

Renal dose

• Adult: PO/IV
CCr 81-100 ml/min 300 mg/day; CCr 61-80 ml/min 250 mg/day; CCr 41-60 ml/min 200 mg/day; 21-40 ml/min 150 mg/day; CCr 10-20 ml/min 100-200 mg/day; CCr 3-9 ml/min 100 mg/day or 100 mg every other day; CCr <3 ml/min 100 mg q24hr or longer or 100 mg every 3rd day

Available forms:
Tabs, scored 100, 300 mg; powder for inj 500 mg/vial

Administer:
PO route

• 
With meals to prevent GI symptoms; may crush, add to foods or fluids

• 
1-2 days before antineoplastic therapy

Intermittent IV INF route

• 
Reconstitute 30-ml vial with 25 ml of sterile water for inj; dilute to desired conc (≤6 mg/ml) with 0.9% NaCl for inj or D
5
for inj; begin inf within 10 hr

Y-site compatibilities:
Acyclovir, aminophylline, amphotericin B lipid complex, anidulafungin, argatroban, atenolol, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, CARBOplatin, caspofungin, ceFAZolin, cefoperazone, cefotetan, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, CISplatin, cyclophosphamide, DACTINomycin, DAUNOrubicin citrate liposome, dexamethasone, dexmedetomidine, docetaxel, DOXOrubicin liposomal, enalaprilat, etoposide, famotidine, fenoldopam, filgrastim, fluconazole, fludarabine, fluorouracil, furosemide, gallium, ganciclovir, gatifloxacin, gemcitabine, gemtuzumab, granisetron hydrochloride, heparin, hydrocortisone phosphate, hydrocortisone succinate, HYDROmorphone, ifosfamide, linezolid injection, LORazepam, mannitol, mesna, methotrexate, metroNIDAZOLE, milrinone, mitoxantrone, morphine, nesiritide, octreotide, oxytocin, PACLitaxel, pamidronate, pantoprazole, pemetrexed, piperacillin, piperacillin-tazobactam, plicamycin, potassium chloride, ranitidine, sodium acetate, sulfamethoxazole-trimethoprim, teniposide, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, vancomycin, vasopressin, vinBLAStine, vinCRIStine, voriconazole, zidovudine, zoledronic acid

SIDE EFFECTS

CNS:
Headache
, drowsiness, neuritis, paresthesia

GI:
Nausea, vomiting, anorexia, malaise
, metallic taste, cramps, peptic ulcer, diarrhea

HEMA:
Agranulocytosis, thrombocytopenia, aplastic anemia, pancytopenia, leukopenia, bone marrow suppression, eosinophilia

INTEG:
Dermatitis, pruritus, purpura, erythema, rash,
Stevens-Johnson syndrome

MISC:
Myopathy, arthralgia, hepatomegaly,
cholestatic jaundice, renal failure, exfoliative dermatitis

PHARMACOKINETICS

Protein binding <1%, half-life 1-2 hr

PO:
Peak 1.5 hr; excreted in feces, urine

IV:
Peak up to 30 min

INTERACTIONS

Increase:
kidney stone formation—ammonium chloride, vit C, potassium/sodium phosphate

Increase:
rash—ampicillin, amoxicillin, avoid concurrent use

Increase:
action of oral anticoagulants, oral antidiabetics, theophylline

Increase:
hypersensitivity, toxicity—ACE inhibitors, thiazides

Increase:
bone marrow depression—antineoplastics (mercaptopurine, azaTHIOprine)

Increase:
xanthine nephropathy, calculi—rasburicase

NURSING CONSIDERATIONS
Assess:

• 
For gout:
joint pain, swelling; may use with NSAIDs for acute gouty attacks; uric acid levels q2wk; uric acid levels should be ≤6 mg/dl, effect may take several wk

• 
CBC, AST, BUN, creatinine before starting treatment, periodically

• 
I&O ratio; increase fluids to 2 L/day to prevent stone formation and toxicity

• 
For rash, hypersensitivity reactions, discontinue allopurinol

Evaluate:

• 
Therapeutic response: decreased pain in joints, decreased stone formation in kidneys, decreased uric acid levels

Teach patient/family:

• 
To take as prescribed; if dose is missed, take as soon as remembered; do not double dose; tabs may be crushed

• 
To increase fluid intake to 2 L/day

• 
To report skin rash, stomatitis, malaise, fever, aching; product should be discontinued

• 
To avoid hazardous activities if drowsiness or dizziness occurs

• 
To avoid alcohol, caffeine; will increase uric acid levels

• 
To avoid large doses of vit C; kidney stone formation may occur

• 
To reduce dairy products, refined sugars, sodium, meat if taking for calcium oxalate stones

Other books

Sapphire Blue by Kerstin Gier
Ritual in the Dark by Colin Wilson
Terraserpix by Mac Park
A Rage to Live by Roberta Latow
Chosen Prey by McCray, Cheyenne
Dead Awakenings by Rebekah R. Ganiere
An Arrangement of Sorts by Rebecca Connolly
Alice-Miranda At School by Jacqueline Harvey